bbo-11818
bbo-11818: developed by 1 company · 1 clinical trial tracked.
bbo-11818 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could bbo-11818 → BBOT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Phase 1 |
Clinical Trials (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
Frequently asked questions
Who is developing bbo-11818?
bbo-11818 is being developed by BridgeBio Oncology Therapeutics, Inc..
How many clinical trials involve bbo-11818?
BioSniper tracks 1 clinical trial involving bbo-11818.